Insulin aspart
- Generic Name
- Insulin aspart
- Brand Names
- Fiasp, Novolog, Novolog Mix, Novomix, Novorapid, Novorapid Penfill, Ryzodeg, Truvelog Mix 30, Kirsty (previously Kixelle), NovoRapid, Insulin aspart Sanofi, NovoMix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 116094-23-6
- Unique Ingredient Identifier
- D933668QVX
- Background
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM), Hyperglycemia during critical illness
- Associated Therapies
- -
Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes
- Conditions
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 220
- Registration Number
- NCT00593255
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Shanghai, Shanghai, China
Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.
- Conditions
- Interventions
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- Rush University Medical Center
- Target Recruit Count
- 176
- Registration Number
- NCT00591227
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
Memory and Insulin in Early Alzheimer's Disease
- First Posted Date
- 2007-12-28
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- Jeff Burns, MD
- Target Recruit Count
- 31
- Registration Number
- NCT00581867
- Locations
- 🇺🇸
University of Kansas Medical Center, Hoglund Brain Imaging Center, Kansas City, Kansas, United States
Initiation of Insulin Aspart in Type 2 Diabetes
- Conditions
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 6
- Registration Number
- NCT00572806
- Locations
- 🇫🇷
Novo Nordisk Investigational Site, MONTPELLIER cedex 5, France
Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes
- Conditions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 61
- Registration Number
- NCT00571935
- Locations
- 🇵🇱
Novo Nordisk Investigational Site, Warszawa, Poland
Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial
- Conditions
- Interventions
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 25
- Registration Number
- NCT00542620
Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 296
- Registration Number
- NCT00537303
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Rugby, United Kingdom
Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma
- Conditions
- Interventions
- First Posted Date
- 2007-08-30
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 10
- Registration Number
- NCT00523042
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Zilina, Slovakia
Metabolic Effect of Insulin Aspart and Human Insulin in Different Doses
- Conditions
- Interventions
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2007-08-09
- Lead Sponsor
- Profil Institut für Stoffwechselforschung GmbH
- Target Recruit Count
- 16
- Registration Number
- NCT00513643
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT00509925
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Guildford, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.